Alvex T, Mintzes B, Lexchin J. (2018). “Medicines information and the regulation of the promotion of pharmaceuticals.” Science and Engineering Ethics, doi: 10.1007/s11948-018-0041-5.
Amiche MA, Abtahi S, Driessen JHM, Vestergaard P, de Vries F, Cadarette SM, Burden AM. (2018). “Impact of cumulative exposure to high-dose oral glucocorticoids on risk of fracture in Denmark: A population-based case-control study.” Arch Osteoporos, 13(1):30.
Amiche AM, Levesque LE, Gomes T, Adachi JD, Cadarette SM. (2018). “Effectiveness of oral bisphosphonates in reducing fracture risk among oral glucocorticoid users: three matched cohort analyses.” K Bone Min Res, 33:419-429.
Amis J, Hirsch P, Lawrence T, McGahan AM, Munir K. (2018). “Inequality, institutions, and organizations.” Organization Studies, 39(9), 1131-1152.
Banerjee A, James R, McGregor M, Lexchin J. (2018). “Nursing home physicians discussing caring for elderly residents: an exploratory study.” Canadian Journal on Aging, 37:133-144.
Ban J, Tadrous M, Lu XA, Cincinelli EA, Cadarette SM. (2018). “History and publication trends in the diffusions and early uptake of indirect comparison meta-analytic methods to study drugs: animated co- authorship networks over time.” BMJ Open, 8(6): e019110.
Chan B, Cadarette SM, Wodchis W, Wong J, Mittmann N, Krahn M. (2018). “Lifetime cost of chronic ulcers requiring hospitalization in Ontario, Canada: a population-based study.” Wound Med, 20:21-34.
Chan CB, Cadarette SM, Wodchis WP, Krahn M, Mittmann N. (2018). “The lifetime cost of spinal cord injury in Ontario Canada: a population-based study from the perspective of the public health payer.” J Spinal Cord Med, 20:21-34.
Charbonneau M, Gagnon MA. (2018). “Surviving niche busters: Main strategies employed by Canadian private insurers facing the arrival of high cost specialty drugs.” Health Policy, 122(12): 1295-1301.
Chit A, Grootendorst P. (2018). “Policy to encourage the development of antimicrobials.” International Journal of Health Governance. 23(2): 101-110.
Clauson K, Breeden EA, Davidson C, Mackey TK. (2018). “Leveraging blockchain technology to enhance supply chain management in healthcare: An exploration of challenges and opportunities in the health supply chain.” Block chain in Healthcare Today. 1(1).
Cuomo RE, Mackey TK. (2018). “Policy and governance solutions for ensuring equitable access to cancer medications in low and middle-income countries.” Ann Transl Med, 6(11):224.
Di Ruggiero E et al. (2018). “What can we learn from collaborations between public health and the food and drinks industry?” Edited by Modi Mwatsama. UK Helath Forum.
Di Ruggiero, E., MacPherson, D., Bajwa, U. (2018). “Directions in Global Public Health Graduate Education.” Oxford Bibliography. DOI: 10.1093/obo/9780199756797-019
Gaffney A, Lexchin J. (2018). “US, Canadian Pharmaceutical Policy Reform Working Group. Healing an ailing pharmaceutical system: Prescription for reform for United States and Canada.” BMJ, 361: k1039.
Gagnon, MA. (2018). “Getting More for Less; Universal Pharmacare as an Alternative to Austerity.” Austerity and Its Alternatives.
Giannakeas V, Zaman T, Cadarette SM, Ban J, Lipscombe L, Narod SA, Kotsopoulos J. (2018). “Breast cancer risk among women using denosumab in a cohort of postmenopausal women from Ontario.” Br J Cancer, In Press.
Grootendorst P, Shim M, Falconi A, Robinson T, Lexchin J. (2018). “Intellectual property protection and drug plan coverage: evidence from Ontario.” International Journal of Health Services.
Gorkinkel I, Lexchin J. (2018). “A call to mandate patient access to personal primacy care medical records across Canada.” CMAJ 190: E869-70.
Guan Q, Sproule BA, Vigod SN, Cadarette SM, Greaves S, Martins D, Gomes T. (2018). “Impact of timing of methadone initiation on perinatal outcomes following delivery among pregnant women on methadone maintenance therapy in Ontario.” Addiction, doi:10.1111/add.14453.
Hunter JA, Lee T, Persaud N. (2018). “A comparison of the content and primary literature support for online medication information provided by Lexicomp and Wikipedia.” J Med Libr Assoc, 106(3): 352- 360.
Klein P, Mahoney K, McGahan AM, Pitelis C. (2018). “Organizational governance adaption: Who is in, who is out, and who gets what.” Academy of Management Review, https://doi.org/10.5465/amr.2014.0459.
Kohler JC, Pico TC, Vian T, Mackey TK. (2018). “The global wicked problem of corruption and its risks for access to HIV/AIDS medicines.” Clinical Pharmacology & Therapeutics. 104(6):1054-1056. https://ascpt.onlinelibrary.wiley.com/doi/full/10.1002/cpt.1172.
Lemmens, T. (2018). “La Gobernanza del Conocimiento en la Industria Farmacéutica desde una Perspectiva de Derechos Humanos” in Hernando Torres Corredor & Diana Colorado Acevedo, eds V Congreso Iberoamericano de Derecho Sanitario, Bogota: Editorial Universidad Nacional de Colombia).
Lemmens T, & Herrera Vacaflor C. “Research Transparency in the Americas: The Need to Coordinate Regulatory Spheres” (2018) 362 British Medical Journal k2493-8.
Lexchin J. (2018). “Canadian status of ‘drugs to avoid’ in 2017: A descriptive analysis.” CMAJ Open, 6: E430-E435.
Lexchin J. (2018). “Composition of Canadian Pain Society Guideline Development Group?” Canadian Family Physician, 64:8.
Lexchin J. (2018). “Crisis at the pharmacy.” CCPA Monitor, 24(6): 24-27.
Lexchin J. (2018). “Health Canada’s use of expedited review pathways and therapeutic innovation, 1995- 2016: cross sectional analysis.” BMJ Open, 8: e023605.
Lexchin J. (2018). “Pharmaceutical company spending on research and development and promotion in Canada, 2013-2016: a cohort analysis.” Journal of Pharmaceutical Policy and Practice, 11:5.
Lexchin J. (2018). “Quality of evidence considered by Health Canada in granting full market authorisation to new drugs with a conditional approval: a retrospective cohort study.” BMJ Open, 8: e020377.
Lexchin J. (2018). “The pharmaceutical industry in contemporary capitalism.” Monthly review, 69(10).
Lexchin J. (2018). “Health Canada’s use of its Notice of Compliance with Conditions drug approval policy: retrospective cohort analysis.” International Journal of Health Services, 2019.
Lexchin J. (2018). “Cost recovery by Health Canada and drug safety: a time-series analysis.” CMAJ Open;6:E471-477.
Lexchin J. (2018). “The term cognition-enhancing medications is misleading.” Canadian Family Physician;64:792.
Lexchin J. (2018). “Editorial.” Journal of Population Therapeutics and Clinical Pharmacology;25:e31- e32
Lexchin J, Kohler JC, Gagnon MA, Crombie J, Thacker P, Shnier A. (2018). “Combating corruption in the pharmaceutical arena.” Indian Journal of Medical Ethics. 3(3): 234-239.
Lundh A, Lexchin J, Mintez B, Schroll JB, Bero L. (2018). “Industry sponsorship and research outcome: systematic review with meta-analysis.” Intensive Care Medicine. Doi: 10.1007/s00134-018-5293-7.
Mackey TK. (2018). “Opioids and the Internet: Convergence of technology and policy issues to address the illicit online sales of opioids.” Health Services Insights, In Press.
Mackey TK. (2018). “Prevalence of falsified and substandard medicines: still an incomplete picture.” JAMA Network Open. 1(4):e181685. doi:10.1001/jamanetworkopen.2018.1685
Mackey TK, Annaloro J. (2018). “Bioexit: Navigating the policy and regulatory pathways for the biotechnology industry in a post-Brexit landscape.” Drug Disc Today. 23(7): 1324-1327.
Mackey TK, Kalyanam J, Klugman J, Kuzmenko E, Gupta R. (2018). “Solution to detect, classify, and report illicit online marketing and sales of controlled substances via twitter: using machine learning and web forensics to combat digital opioid access.” J Med Internet Res, 20(4): e10029.
Mackey TK, Kohler JC, Vian T. (2018). “The sustainable development goals as a framework to combat health-sector corruption.” Bull World Health Organ, 96:634-643. http://dx.doi.org/10.2471/BLT.18.209502.
Majdalani EC, Sirotich E, Kohler JC. (2018). “The effect of corruption on health service accessibility for women: a systematic review.” PROSPERO.
McGahan, AM. (2018). “Freedom in Scholarship: Lessons from Atlanta.” Academy of Management Review, 43(2): 173-178.
Morgan SG, Persaud N. (2018). “New generic pricing scheme maintains high prices and risks of shortages.” CMAJ, 190(14): E410-E411.
Moscou K. (2018). “Pharmacogovernance and postmarket drug safety in Kenya.” In Press.
Mwatsama M, Di Ruggiero E. (2018). “Lessons from interactions between public health and the food and drinks industry.” The Lancet Global Health Blog. 1(1):1-13.
Paschke A, Dimancesco D, Vian T, Kohler JC, Forte G. (2018). “Increasing transparency and accountability in national pharmaceutical systems”. Bulletin of the World Health Organization. 96(11):782-79. http://dx.doi.org/10.2471/BLT.17.206516
Persaud N. (2018). “Essential medicines and the challenges in the Evidence-Based Manifesto.” BMJ Evidence-Based Medicine. doi:10.1136/bmjebm-2018-110979.
Persaud N. (2018). “Fantastic idea: Admit patients to hospital administratively so they can access medications.” Can Fam Physician, 64(2):98.
Persaud N. (2018). “Rebuttal: Will the new guidelines harm more people that they help?” Can Fam Physician, 64(2): 102-104.
Persaud N, Meaney C, El-Emam K, Moineddin R, Thorpe K. (2018). “Doxylamine-pyridoxine for nausea and vomiting of pregnancy randomized placebo controlled trials: Prespecified analyses and reanalysis.” PLOS One, 13(1): e1089978.
Persaud N, Paupacia A, Azarpazhooh A, Birken C, Hoch J, Isaranuwatchal W, Maguire J, Mamdani M, Thorpe K, Allen C, Mason D, Kowal C, Bazeghi F, Parkin P. (2018). “Xylitol for the prevention of acute otitis media episodes in children aged 2-4 years: protocol for a pragmatic randomized controlled trial.” BMJ Open, 8: e020941.
Reynolds E, Guénette L, Lexchin J, Cassels A, Wilkes MS, Durrieu G, Beaulieu MD, Mintzes B. (2018). “Reconciling a ‘pleasant exchange’ with evidence of information bias: a three-country study on pharmaceutical sales visits in primary care.” Health Policy, 122:25-255.
Schiff GD, Marin SA, Eidelman DH, Volk LA, Ruan E, Cassel C, Galanter W, Johnson M, Jutel A, Kroenke K, Lambert BL, Lexchin J, Myers S, Miller A, Mushlin S, Sander L, Sheikh A. (2018). “Ten principles for more conservative, care-fill diagnosis.” Annals of Internal Medicine, doi:10.7326/M18- 1468.
Simeonova M, de Vries F, Pouwels S, Driessen JHM, Leufkens HGM, Cadarette SM, Burden AM. (2018). “Increased risk of all-cause mortality associated with domperidone: a use in Parkinson’s patients: a population-based cohort study in the UK.” Br J Clin Pharmacol, 84(11): 2551-2561.
Taglione MS, Boozary A, Persaud N. (2018). “Medication coverage for lawmakers may worsen access for everyone else.” Prev Med, 108:67-73.
Wiktorowicz M, Moscou K, Lexchin J. (2018). “Transnational pharmacogovernance: the jazz of pharmaceutical policy convergence.” Globalization and Health, 14:86.
Wong L, Hayes KN, Cadarette SM. (2018). “Bad to the bone: how pharmacies can help minimize drug- induces fracture risk.” Pharmacy Practice+, 5(10): 18-23.
Xu Y, Mamdani M, Juurlink DN, Gomes T, Cadarette SM, Tadrous M. (2018). “Analysis of trends in insulin utilization and spending across Canada from 2010 to 2015.” Can J Diabetes, In Press.
Ziai H, Zhang R, Chan AW, Persaud N. (2018). “Search for unpublished data by systematic reviewers: an audit.” BMJ Open, 7(10) e017737.